Get the Stockscreener App
13.28
0.84%
0.11
After Hours:
13.48
0.20
+1.51%
Neuropace Inc stock is traded at $13.28, with a volume of 316.91K.
It is up +0.84% in the last 24 hours and up +15.18% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$13.17
Open:
$13.17
24h Volume:
316.91K
Relative Volume:
1.14
Market Cap:
$435.58M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-10.46
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
+1.30%
1M Performance:
+15.18%
6M Performance:
+17.73%
1Y Performance:
+103.06%
1-Day Range:
$12.89
$13.91
1-Week Range:
$12.43
$13.91
52-Week Range:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
13.28 | 429.99M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
133.94 | 231.14B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.83 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
383.10 | 146.12B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
87.00 | 105.64B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.77 | 45.60B | 5.54B | 4.18B | 623.10M | 7.00 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
NeuroPace secures USD 75M in debt financing - Medical Buyer
BNP Paribas Financial Markets Acquires New Holdings in NeuroPace, Inc. (NASDAQ:NPCE) - Defense World
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
NeuroPace Secures $75 Million Credit Facility with MidCap - TipRanks
NeuroPace Secures $75 Million Credit Facility From MidCap Financial - marketscreener.com
NeuroPace secures $75 million credit facility with MidCap Financial - Investing.com Australia
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc.Contact Levi & Korsinsky - ACCESS Newswire
Neuropace IncEnters Into Credit Agreement With Midcap Funding Iv Trust - marketscreener.com
NeuroPace, Inc. Secures $75 Million Credit Facility from MidCap Financial to Support Growth Initiatives - Nasdaq
NeuroPace Secures Up to $75 Million in Debt Financing - TradingView
$75M Financing Fuels NeuroPace's Epilepsy Treatment Expansion: 5 Key Growth Initiatives Revealed - Stock Titan
Lost Money on NeuroPace, Inc. (NPCE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation - ACCESS Newswire
Did NeuroPace, Inc. (NPCE) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
FY2028 EPS Estimates for NeuroPace Cut by Leerink Partnrs - MarketBeat
Research Analysts Set Expectations for NeuroPace Q3 Earnings - MarketBeat
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc.NPCE - FinancialContent
Cantor Fitzgerald maintains overweight rating on NeuroPace stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald maintains overweight rating on NeuroPace stock - Investing.com
NeuroPace, Inc. (NPCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc.NPCE - PR Newswire
NeuroPace, Inc. (NASDAQ:NPCE) Shares Sold by Millennium Management LLC - MarketBeat
Q2 Earnings Estimate for NeuroPace Issued By HC Wainwright - MarketBeat
Q3 Earnings Estimate for NeuroPace Issued By Leerink Partnrs - Defense World
Q2 Earnings Forecast for NeuroPace Issued By HC Wainwright - Defense World
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Shares Bought by Northern Trust Corp - MarketBeat
FY2028 EPS Estimates for NeuroPace Decreased by Analyst - Defense World
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud - ACCESS Newswire
Point72 Asset Management L.P. Takes $369,000 Position in NeuroPace, Inc. (NASDAQ:NPCE) - MarketBeat
NeuroPace (NASDAQ:NPCE) Now Covered by HC Wainwright - Defense World
NeuroPace falls after setback in trial for neuromodulation system - MSN
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace (NPCE) Initiates Coverage with "Buy" Rating by HC Wain - GuruFocus
H.C. Wainwright sets $18 target on NeuroPace stock with Buy rating - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, ... - Eagle-Tribune
NeuroPace Inc (NPCE) Shares Gap Down to $11.75 on May 28 - GuruFocus
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial - Yahoo Finance
NeuroPace reports initial one-year outcomes from trial of RNS System - Yahoo Finance
HC Wainwright & Co. Initiates Coverage of NeuroPace (NPCE) with Buy Recommendation - Nasdaq
Analyst Expectations For NeuroPace's Future - Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright Initiates NeuroPace at Buy With $18 Price Target - marketscreener.com
Transcript : NeuroPace, Inc.Special Call - marketscreener.com
NeuroPace (NPCE) Receives Positive Initiation from H.C. Wainwrig - GuruFocus
NeuroPace (NPCE) Shares NAUTILUS Study Results on RNS System | N - GuruFocus
NeuroPace reports mixed results in epilepsy study By Investing.com - Investing.com India
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.64%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):